
CL Educate revenues were up about 30% in Q1 FY’24, with strong growth in both EdTech and MarTech business. The management has been saying it is focused on delivering strong growth henceforth, the Q1 results show it is walking the talk. Drilling down, EdTech and MarTech registered 33% and 23%…
Read More
The initial reaction of the market to the Q4 and full year FY23 results of CL Educate (NSE: CLEDUCATE, BSE: 540403) was negative. The stock fell 2% on 11-May-23 to close at Rs 53.15, the Thursday of the last week, the day the results were declared. However, the next day,…
Read More
Growth momentum continued in Q3 FY23 despite Q3 traditionally being the weakest quarter due to exams. EdTech and MarTech revenues were up 31% and 22% respectively on a y-o-y basis. CL has crossed FY22 revenue and EBITDA in 9m FY23. While much of this recovery is due to return to…
Read More
After the FY21 year-end result of CL Educate, we wrote in June’21: In fact, when it looks back at FY21 many years later, it may find that it was a key turning point in its corporate journey. Then after Q1 FY22 results, we wrote in Aug’21: After 2 years –…
Read More
We recorded 79 VC/PE transactions pertaining to the global life sciences sector for September 2021, aggregating to a sum of USD 3.3B, as against 96 transactions and USD5.6B in Sep’20. The USA recorded 49 transactions aggregating to a total investment of USD 2.2B. China reported a totally out of character…
Read More
We recorded 114 VC/PE transactions pertaining to the global life sciences sector for June 2021, aggregating to a sum of USD 6.47B. The USA recorded 69 transactions aggregating to a total investment of USD 3.26B. China reported investment of USD 886m from 11 VC/PE transactions. Rest of the world accounted…
Read More
FY21 didn’t turn out too bad for CL Educate. In fact, when it looks back at FY21 many years later, it may find that it was a key turning point in its corporate journey. That is not to say it was a rosy FY21 for CL. The global scourge Covid…
Read More
Chemcrux Enterprises suffered only a 7% revenue drop and 17% EBITDA drop in FY21, despite losing over 23% of productive days due to plant closure, and Covid related production constraints in FY21. Highlights of the FY21 results: FY21 full year sales came in at Rs 533m, 7% drop over sales…
Read More